[Ip-health] New Tufts study on R&D costs
Michael H Davis
m.davis at csuohio.edu
Fri Nov 14 09:47:09 PST 2014
The Tufts "study" is one of the longest running scams in health IP. I have talked to these guys and they've told me they trust the drug companies to be honest. There's no way to the truth when you start there.
Jamie, it'll be higher, even though there's less new drugs. Why? Well if your auditors say they trust you, wouldn't you give them higher numbers? This "study" doesn't merit publication.
Prof. Mickey Davis
Cleveland State University
2121 Euclid Avenue, LB 234
Cleveland, OH 44115-2214
Cleveland-Marshall College of Law
1801 Euclid Avenue
Law Building, LB 234
Admitted to practice before the United States Patent and Trademark Office, Reg. No. 45,863
-------- Original message --------
From: Jamie Love <james.love at keionline.org>
Date:11/14/2014 12:36 PM (GMT-05:00)
To: Ip-health <ip-health at lists.keionline.org>
Subject: [Ip-health] New Tufts study on R&D costs
Next week, a new version of the Tufts study on R&D costs will be released.
KEI will give $50 to the person who comes the closed in predicting the new
figure for the cost of R&D for the lead indication of a new chemical entity.
An abstract of the earlier 2003 study,"The price of innovation: new
estimates of drug development costs" is available here:
The 2003 study put the number at $802 million (not $800 million, but $802
million), in 2000 dollars.
As I said, $50 for the closest estimate, published on IP-Health, before the
new number is announced (or leaked).
James Love. Knowledge Ecology International
KEI DC tel: +1.202.332.2670, US Mobile: +1.202.361.3040, Geneva Mobile:
Ip-health mailing list
Ip-health at lists.keionline.org
More information about the Ip-health